LFA-1– and VLA-4–Mediated Adhesion of Leukemic Cells Derived From Both BM and Peripheral Blood
Patient No. . | CD10+ (%) . | CD104-150 (mean) . | LFA-1 Adhesion4-151 . | VLA-4 Adhesion4-151 . | ||||
---|---|---|---|---|---|---|---|---|
Medium . | PMA . | KIM185 . | Medium . | PMA . | TS2/16 . | |||
2 | ||||||||
BM | 94‡ | − | +/− | + | ++ | ++ | ++ | +++ |
PB | 16 | + | − | − | − | − | − | +++ |
3 | ||||||||
BM | 66 | ++ | +/− | + | ++ | ++ | ++ | +++ |
PB | 61 | ++ | − | + | ++ | ++ | ++ | +++ |
5 | ||||||||
BM | 73 | +++ | − | +/− | +++ | +++ | +++ | +++ |
PB | 37 | +++ | − | − | ++ | ++ | ++ | +++ |
12 | ||||||||
BM | 38 | +++ | − | − | ++ | ++ | +++ | +++ |
PB | 69 | +++ | − | +/− | ++ | ++ | ++ | +++ |
17 | ||||||||
BM | 100 | ++ | − | − | − | ++ | ++ | +++ |
PB | 100 | ++ | − | − | − | ++ | ++ | +++ |
18 | ||||||||
BM | 97‡ | − | − | − | − | + | ++ | ++ |
PB | 10 | + | − | + | ++ | ++ | ++ | +++ |
Patient No. . | CD10+ (%) . | CD104-150 (mean) . | LFA-1 Adhesion4-151 . | VLA-4 Adhesion4-151 . | ||||
---|---|---|---|---|---|---|---|---|
Medium . | PMA . | KIM185 . | Medium . | PMA . | TS2/16 . | |||
2 | ||||||||
BM | 94‡ | − | +/− | + | ++ | ++ | ++ | +++ |
PB | 16 | + | − | − | − | − | − | +++ |
3 | ||||||||
BM | 66 | ++ | +/− | + | ++ | ++ | ++ | +++ |
PB | 61 | ++ | − | + | ++ | ++ | ++ | +++ |
5 | ||||||||
BM | 73 | +++ | − | +/− | +++ | +++ | +++ | +++ |
PB | 37 | +++ | − | − | ++ | ++ | ++ | +++ |
12 | ||||||||
BM | 38 | +++ | − | − | ++ | ++ | +++ | +++ |
PB | 69 | +++ | − | +/− | ++ | ++ | ++ | +++ |
17 | ||||||||
BM | 100 | ++ | − | − | − | ++ | ++ | +++ |
PB | 100 | ++ | − | − | − | ++ | ++ | +++ |
18 | ||||||||
BM | 97‡ | − | − | − | − | + | ++ | ++ |
PB | 10 | + | − | + | ++ | ++ | ++ | +++ |